Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 13/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539169 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2539170 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL373002 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL701081 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL373186 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL8511266 | 0.92 | CHRNA7 (0.85) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL701883 | 0.84 | CHRNA7 (0.73) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL699598 | 0.83 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL6155498 | 0.83 | CHRNA7 (0.71) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL700727 | 0.83 | CHRNA7 (0.71) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2465501-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of preparation | Targacept Inc. (US) | 2012-06-20 | — | — | EP | claimed |
| US-8119659-B2 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-21 | — | — | US | claimed |
| US-20110263859-A1 | (2S, 3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | claimed |
| EP-2182949-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | Targacept Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| US-20090048290-A1 | 2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL-BENZYOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TRAMES BIO, INC. | 2009-02-19 | — | — | US | claimed |
| WO-2009018505-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20170119746-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | ATTENUA, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170119746-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | ATTENUA, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170119746-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | ATTENUA, INC. | 2017-05-04 | — | — | US | disclosed |
| EP-2431037-B1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof | ATTENUA INC (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2465501-B1 | Method for the preparation of (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide | ATTENUA INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9173876-B2 | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide | ATTENUA, INC. | 2015-11-03 | — | — | US | disclosed |
| US-9173876-B2 | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide | ATTENUA, INC. | 2015-11-03 | — | — | US | disclosed |
| WO-2010085724-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | TARGACEPT, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010056622-A1 | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2185152-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | Targacept Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-2182949-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | Targacept Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090048290-A1 | 2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL-BENZYOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TRAMES BIO, INC. | 2009-02-19 | — | — | US | disclosed |
| WO-2009018505-A1 | (2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018511-A2 | ALPHA7 NACHR AGONISTS FOR TREATING OR PREVENTING METABOLIC DISORDERS | TARGACEPT, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048290-A1 | 2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL-BENZYOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | HCN3, HCN2, NTSR2 | CHRNA7 61/4885CHRNB2 7/4885CHRNA4 59/4885 |
| US-20110263859-A1 | (2S, 3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF | HCN3, NTSR2, HCN2 | CHRNA7 63/4885CHRNB2 7/4885CHRNA4 59/4885 |
| US-20170119746-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | CHRNA2, CHRNA3, CHRNB2 | CHRNA7 9/4885CHRNB2 3/4885CHRNA4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.